# Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

> **NCT02142868** · — · NO_LONGER_AVAILABLE · sponsor: **Pfizer**

## Conditions studied

- Advanced Breast Cancer (Female)

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02142868
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142868, "Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02142868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*